Program
Please note that this symposium will take place as an in-person event in Montreal and will not live-stream content for virtual participation. The symposium content will be recorded and made available as an on-demand program after the symposium. Please visit the registration page for details.
CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
*-Short talk from proffered abstract
Monday, June 10
Tuesday, June 11
- Plenary Session 1: Chemical Biology Tools to Advance Synthetic Lethality
- Plenary Session 2: Mechanisms of Synthetic Lethality
- Plenary Session 3: Clinical Translation of DNA Damage Synthetic Lethality
Wednesday, June 12
- Plenary Session 4: Synthetic Lethality at Scale
- Plenary Session 5: New Concepts in Synthetic Lethality
- Plenary Session 6: Synthetic Lethality of Residual Disease
Thursday, June 13
- Plenary Session 7: New Technologies to Discover Synthetic Lethality
- Plenary Session 8: Translating the Next Synthetic Lethalities
- Closing Remarks
welcome and introductions
6-6:05 P.M.
- Michael A. Erb, The Scripps Research Institute, La Jolla, California
- Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
- E. Alejandro Sweet-Cordero, University of California, San Francisco, California
- Kris C. Wood, Duke University School of Medicine, Durham, North Carolina
Opening Plenary
6-7 P.M.
CME-Eligible
- Scientific Keynote
Exploiting pathway activation as a new form of synthetic lethality
William R. Sellers, Broad Institute and Dana-Farber Cancer Institute, Cambridge, Massachusetts
OPENING RECEPTION
7-8:30 P.M.
CONTINENTAL BREAKFAST
7-8 A.M.
PLENARY SESSION 1: Chemical Biology Tools to Advance Synthetic Lethality
8-10 a.m.
CME-Eligible
Session Chair: Fleur M. Ferguson, UC San Diego, La Jolla, California
- Exploiting metabolic vulnerabilities in PDAC to overcome K-Ras inhibitor resistance
Fleur M. Ferguson, UC San Diego, La Jolla, California - Chemoproteomic discovery of a synthetic lethal allosteric inhibitor of WRN helicase
Matthew P. Patricelli, Vividion Therapeutics, San Diego, California - Redirecting FOXA1 pioneering function with covalent small molecules
Michael A. Erb, The Scripps Research Institute, La Jolla, California - KIF18A inhibition, via ATX020, leads to mitotic arrest and robust anti-tumor activity through a synthetic lethal interaction with chromosome instability*
Maureen Lynes, Accent Therapeutics, Lexington, Massachusetts - Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer*
Yonghao Yu, Columbia University Vagelos College of Physicians and Surgeons, New York, New York
BREAK
10-10:30 A.M.
PLENARY SESSION 2: Mechanisms of Synthetic Lethality
10:30 A.M.-12:30 P.M.
CME-Eligible
Session Chair: Zuzana Tothova, Dana-Farber Cancer Institute, Boston, Massachusetts
- Therapeutic vulnerabilities of cohesin-mutant myeloid malignancies
Zuzana Tothova - Synthetic vulnerabilities in cancers driven by chromatin remodeler mutations
Charles W.M. Roberts, St. Jude Children’s Research Hospital, Memphis, Tennessee - The long isoform of RAP1GDS1 is a synthetic vulnerability in RAS-driven lung adenocarcinoma
E. Alejandro Sweet-Cordero, University of California San Francisco, San Francisco, California - Mechanisms of therapeutic vulnerability of mismatch repair defective cancers to RNA polymerase I inhibitors*
Marikki Laiho, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland - Computational discovery of paralog dependencies drives target identification in lung cancer*
Siobhan O’Brien, Fred Hutchinson Cancer Center, Seattle, Washington
LUNCH (ON OWN)
12:30-2:30 P.M.
Plenary Session 3: Clinical Translation of DNA Damage Synthetic Lethality
2:30-4:30 P.M.
CME-Eligible
Session Chair: Michael A. White, Ideaya Biosciences, San Diego, California
- Exploiting tumor selective vulnerabilities with structure based drug design
Michael A. White - DNA repair inhibition and synthetic lethal opportunities
Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts - Targeting genome instability in cancer: Translating synthetic lethal biology into the clinic
Michael J. Zinda, Repare Therapeutics Inc., Cambridge, Massachusetts - CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition*
Luc Furic, Peter MacCallum Cancer Centre, Melbourne, Australia - DNA repair inhibition via targeting ATR activates cGAS/STING signaling, promotes anti-tumor immunity, and is a synthetic lethal strategy to augment immunotherapy response in preclinical models and clinical samples of small cell lung cancer*
Triparna Sen, Icahn School of Medicine at Mount Sinai, New York, New York
Poster session A and reception
4:30-7 P.M.
CONTINENTAL BREAKFAST
7-8 A.M.
Plenary Session 4: Synthetic Lethality at Scale
8-10 A.M.
CME-Eligible
Session Chair: Francisca Vazquez, Broad Institute, Cambridge, Massachusetts
- Towards mapping the landscape of cancer vulnerabilities
Francisca Vazquez - Synthetic lethal approaches for targeting oncogenic transcription
Ron Firestein, Hudson Institute of Medical Research, Clayton, Australia - Identifying novel therapeutic vulnerabilities in AML: From discovery to targeting
Aniruddha Deshpande, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California - Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions*
Julia V. Milne, Peter MacCallum Cancer Centre, Melbourne, Australia - Targeting mechanisms of dosage compensation to selectively kill aneuploid cancer cells*
Hajime Okada, Tel Aviv University, Tel Aviv, Israel
BREAK
10-10:30 A.M.
Plenary Session 5: New Concepts in Synthetic Lethality
10:30 A.m.-12:30 p.M.
CME-Eligible
Session Chair: Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
- Synthetic lethal vulnerabilities in pediatric cancer
Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts - Identifying and targeting cellular vulnerabilities induced by cancer aneuploidy
Uri Ben-David, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel - Emerging synthetic vulnerabilities in oncogene-driven lung cancer
Trever G. Bivona, University of California San Francisco, San Francisco, California - Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal cancers*
Tim Arnoldus, Netherlands Cancer Institute, Amsterdam, Netherlands - CDK12 loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality*
Jean C. Tien, University of Michigan, Ann Arbor, Michigan
LUNCH ON OWN
12:30-2:30 P.M.
Plenary Session 6: Synthetic Lethality of Residual Disease and Novel Drug Combinations
2:30-4:30 P.M.
CME-Eligible
Session Chair: Kris C. Wood, Duke University, Durham, North Carolina
- Synthetic dependencies arising during tumor evolution
Kris C. Wood - Overcoming targeted therapy resistance in acute leukemia
Shruti Bhatt, National University of Singapore (NUS), Singapore - Exploiting glutathione deficiency to identify targetable metabolic vulnerabilities in tumor cells
Poul H.B. Sorensen, British Columbia Cancer Research Institute and University of British Columbia, Vancouver, British Columbia, Canada - Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibition*
Qiyun Deng, McGill University, Montreal, Quebec, Canada - KAT6A/B and Menin-MLL complexes coordinately regulate estrogen receptor-driven gene expression programs in breast cancer*
Sarah Naomi Olsen, Dana-Farber Cancer Institute, Boston, Massachusetts
Poster session b and reception
4:30-7 P.M.
CONTINENTAL BREAKFAST
7-8 A.M.
Plenary Session 7: New Technologies to Discover Synthetic Lethality
8-10 A.M.
CME-Eligible
Session Chair: Francisco J. Sánchez Rivera, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
- Mapping environmentally induced cancer dependencies
Luke A. Gilbert, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California - High throughput evaluation of genetic variants with prime editing sensor libraries
Francisco J. Sánchez Rivera, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts - Mechanisms of splicing dysregulation in cancer
Kristen L. Karlin, Baylor College of Medicine, Houston Texas - Detecting pairwise and higher-order antagonistic epistatic effects among somatic cancer genotypes to discover synthetic lethality*
Jorge A. Alfaro-Murillo, Yale University, New Haven, Connecticut - Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in KRAS mutant cancers*
Rand Arafeh, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
BREAK
10-10:30 A.M.
Plenary Session 8: Translating the Next Synthetic Lethalities
10:30 A.m.-12:30 p.M.
CME-Eligible
Session Chair: Jolanta E. Grembecka, University of Michigan, Ann Arbor, Michigan
- Targeting epigenetic complexes in leukemia
Jolanta E. Grembecka - RNA-modifying enzyme inhibitors as synthetic lethal cancer therapeutics
Serena J. Silver, Accent Therapeutics, Lexington, Massachusetts - Identifying and deconstructing chemical synthetic lethal interactions for the development of combinatorial therapies
Karen M. Cichowski, Brigham and Women’s Hospital, Boston, Massachusetts - Discovery of selective BRM (SMARCA2) ATPase inhibitors for the treatment of BRG1(SMARCA4) mutant cancers*
Janice Y. Lee, Foghorn Therapeutics, Cambridge, Massachusetts - Investigating vulnerabilities associated with chromosome arm aneuploidy in cancer*
Nadja Zhakula, Columbia University Vagelos College of Physicians and Surgeons, New York, New York
CLOSING REMARKS
12:30 P.m.
CME-Eligible
- Michael A. Erb, The Scripps Research Institute, La Jolla, California
- Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
- E. Alejandro Sweet-Cordero, University of California, San Francisco, California
- Kris C. Wood, Duke University School of Medicine, Durham, North Carolina